27 April 2007, London UK: Ark Therapeutics Group plc ('Ark' or the 'Company')
today announces that it has been informed by the European medicines regulatory
authority, the EMEA, that in their opinion marketing approval cannot yet be
given for CereproTM, Ark's novel gene-based medicine for the treatment of
operable high grade glioma (malignant brain tumour). Although detailed feedback
has yet to be received from the EMEA, it is understood that the EMEA takes the
view that there is not yet a sufficient weight of clinical evidence from the
limited number of patients included in the Phase II data to conclude that the
risk benefit for patients has been proven beyond doubt.
